Abcam, ab183532, Anti-DLL4 antibody

Size: 100µL
Goat Polyclonal DLL4 antibody. Suitable for WB and reacts with Human, Mouse, Rat samples. Cited in 6 publications. Immunogen corresponding to Synthetic Peptide within Human DLL4 aa 550-600.
Key facts
Host species:Goat,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Rat, Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Synthetic Peptide within Human DLL4 aa 550-600. The exact immunogen used to generate this antibody is proprietary information.Q9NR61

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Purification notes-ab183532 was purified from goat serum by ammonium sulfate precipitation followed by antigen affinity chromatography using the immunizing peptide., Storage buffer-pH: 7.3Preservative: 0.02% Sodium azideConstituents: 99% Tris buffered saline, 0.5% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
DLL4 also known as Delta-like ligand 4 is a member of the Delta/Serrate/Lag-2 family. This target is a single-pass type I membrane protein with a molecular weight of approximately 65 kDa. It features prominently in the vascular endothelium where it impacts angiogenic activity. DLL4 acts as a ligand for Notch receptors initiating a signaling cascade important to cell fate decisions. DLL4 expression occurs mainly on the arterial endothelium and the tumor vasculature highlighting its significance in angiogenesis.
Biological function summary
DLL4 engages in precise regulation of angiogenesis and vascular development. It participates in the Notch signaling pathway playing an integral role in controlling endothelial cell proliferation differentiation and migration. DLL4 does not operate in isolation; instead it functions as part of the Notch receptor-ligand complex. This relationship effectively regulates the sprouting of new blood vessels ensuring proper vascular patterning and functional blood supply.
Pathways
DLL4 links directly to the Notch signaling and VEGF (vascular endothelial growth factor) pathways both of which play critical roles in vascular development and homeostasis. Through the Notch pathway DLL4 interacts with Notch1 and Notch4 receptors facilitating communication that inhibits endothelial cell proliferation distinguishing it from other pro-angiogenic factors. Its relationship with the VEGF pathway allows DLL4 to modulate angiogenic processes balancing vessel sprouting by opposing excessive VEGF-induced activities.
Aberrations of DLL4 influence cancer and cardiovascular diseases. Overexpression and dysregulation of DLL4 have been observed in various cancers where it contributes to tumor angiogenesis promoting the growth and spread of cancer cells. In cardiovascular disorders dysfunctional DLL4 signaling impacts vascular development which can lead to fatal arteriovenous malformations. In these conditions DLL4 interacts with proteins like Notch1 and VEGF underlining its critical involvement in pathological angiogenesis and vessel formation.